moneyheap
GILD · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Gilead Sciences Inc (GILD) stock moving?
Gilead has moved from about $156 on Oct 23 to a $170.87 close on Nov 10, a gain of roughly 9%, after reporting Q3 results on Oct 29. The 8-K excerpt does not include the reported figures, so this analysis relies on the price action and the news flow. The strongest recent evidence is clinical and regulatory: Phase 3 IDEAL data for Livdelzi showed 75.4% ALP normalization versus 16.1% on placebo, PURPOSE 5 showed higher persistence for twice-yearly lenacapavir, and the FDA approved a long-acting lenacapavir for HIV prevention on Nov 2. Analysts have lifted targets repeatedly, from Bernstein at $175 and JPMorgan at $190 to Maxim at $200, DZ Bank at $191 and Daiwa at $174, which averages about $184 and implies roughly 8% upside from the last close. The price has been volatile: it peaked intraday at $176.58 on Nov 5 on 11.4M shares, then closed at $167.57 the same day, a reversal that points to supply near $175. Volume was heavy on Oct 30 (11.4M) and Nov 5, and has eased to about 4.8M on Nov 10. Holding above the $164-167 zone since Nov 6 suggests buyers are defending that area. Risks include the pending FDA decision on a new cell therapy, which adds event risk, and a generic lenacapavir that could widen access in lower-income countries at lower prices.
News behind the analysis
- Gilead Highlights Strong Trial Results in HIV Prevention and Liver DiseaseGilead reported high persistence for its twice-yearly HIV shot lenacapavir and a strong Phase 3 response for Livdelzi in primary biliary cholangitis.
- Daiwa Securities Adjusts Gilead Sciences Price Target to $174 From $150Daiwa Securities raised its price target on Gilead from $150 to $174.
- Gilead Sciences Announces Positive Results from PURPOSE 5 Trial for LenacapavirIn the PURPOSE 5 trial, twice-yearly lenacapavir showed significantly higher persistence and zero HIV acquisitions versus daily oral PrEP.
- Gilead Sciences Reports Phase 3 IDEAL Success For Livdelzi In PBC, With 75.4% Achieving ALP Normalization At Week 52 Vs 16.1% Placebo; Serious Adverse Events 3.1% Livdelzi Vs 12.9% Placebo; None Related To DrugPhase 3 IDEAL data showed 75.4% of Livdelzi-treated PBC patients reached ALP normalization at week 52 versus 16.1% on placebo, with serious adverse events of 3.1% versus 12.9%.
- Maxim Group Raises Gilead Sciences Price Target to $200Maxim Group raised its Gilead price target from $165 to $200.
- DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167DZ Bank raised its Gilead price target from $167 to $191.
- FDA Approves Long-Acting HIV Prevention DrugThe FDA approved a long-acting injectable version of Gilead's lenacapavir for HIV prevention.
- FDA Grants Tentative Approval for Generic Lenacapavir for HIV Prevention in Global MarketsThe FDA granted tentative approval for a generic twice-yearly lenacapavir to expand access in 120 low- and middle-income countries.
- Bernstein Increases Price Target for Gilead SciencesBernstein raised its Gilead price target from $160 to $175.
- JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $190JP Morgan kept its Overweight rating on Gilead and raised its price target to $190.
About Gilead Sciences Inc
Gilead Sciences is a large California-based biopharmaceutical company best known as the leading maker of HIV medicines, including the top-selling treatment Biktarvy and the twice-yearly HIV prevention shot Yeztugo. It is expanding beyond HIV into cancer, liver disease and inflammation, partly through acquisitions such as Arcellx, Ouro Medicines and Tubulis in 2026.
How it makes money
Gilead earns nearly all of its revenue by selling prescription drugs, and HIV medicines make up the large majority. Biktarvy alone brought in about $14 billion of roughly $29 billion in total revenue in 2025. Other sales come from cancer drugs (Trodelvy and the cell therapies Yescarta and Tecartus), liver-disease drugs (Livdelzi plus hepatitis B and C treatments) and the COVID antiviral Veklury, whose sales are shrinking. A smaller amount comes from royalties and collaborations. The company expects about $31 billion in total revenue for 2026.
What usually moves GILD
- HIV treatment and prevention (PrEP) sales growth
- Clinical trial results and FDA approvals
- New drug launches in cancer and HIV
- US drug pricing policy and patent expirations
- Acquisitions and related R&D charges